Tag: Revalesio

Stroke Patients Discharged from Hospital Sooner when Administered Revalesio’s RNS60; New Statistically Significant Finding from Revalesio’s Phase 2 Clinical Trial

Neuro by Comments are Disabled

Reduced hospital stays with more patients discharged to home when treated with RNS60 Results presented during oral presentation at the American Academy of Neurology 2025 Annual Meeting TACOMA, Wash., April 9, 2025 /PRNewswire/ — Revalesio, a clinical-stage pharmaceutical company…

Continue Reading →

Revalesio Announces New Analyses from Phase 2 RESCUE Study of RNS60 in Patients with Acute Ischemic Stroke in Oral Presentation at the International Stroke Conference 2025

Neuro by Comments are Disabled

Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient’s recovery TACOMA, Wash.,…

Continue Reading →

Revalesio Announces the Design of RESCUE, a Phase 2 Trial of RNS60 in Acute Ischemic Stroke, and the Presentation of Preclinical Data at the International Stroke Conference 2022

Neuro by 0 comments

TACOMA, Wash.–(BUSINESS WIRE)–Revalesio, a clinical-stage pharmaceutical company developing treatments for neurological diseases, presented the design of its recently launched RESCUE Phase 2 clinical trial evaluating RNS60 as a treatment for large vessel occlusion acute ischemic stroke (AIS), as well as new preclinical data supporting the advancement of RNS60 for AIS. […]

Continue Reading →